Teva Pharmaceutical Industries Limited · TEVA · Next earnings

Teva Pharmaceutical Industries Limited reports Tuesday, Nov 3, 2026

TEVA reports before market open with consensus EPS at $0.72 and revenue at $4.23B. Last quarter: Teva’s innovative portfolio grows as revenue guidance rises

Reports Before market open0 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $0.72 Calendar consensus
Consensus revenue $4.23B Calendar consensus
Report date Nov 3, 2026 Tuesday, date estimated
Session Before market open 0 days away

Where TEVA left off: FY2026 Q3

Full report

Teva’s innovative portfolio grows as revenue guidance rises

EPS surprise — Reported — vs $0.72
Revenue surprise — Reported — vs $4.23B
Stock move +3.3% Event window
Subsequent drift 0.0% Up to 20 sessions

Management raised full-year revenue guidance to $16.7–$17 billion and set an operating-margin target of 22.6%–23.1% (27.8%–28.2% excluding IPR&D).

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Potential IRA-related pricing and volume pressure on AUSTEDO.
  • Execution and payer-access risks for WELTRUZA and BXCL501.
  • Litigation risk affecting biosimilar launches, including SIMPONI and ENTYVIO.

Questions analysts left open

  • How gross margins can expand in 2027 and what will drive that improvement.
  • The effect of IRA policy on AUSTEDO and Teva’s pricing strategy.
  • The timing and potential 2027 contribution of WELTRUZA, ecopipam and BXCL501.

Ask FN2 about TEVA next report

Transcript, numbers and history already loaded
What should I watch for in TEVA's next earnings report?How did TEVA guide last quarter, and is consensus above or below that?Give me the bull and bear case going into TEVA earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the TEVA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent TEVA quarters

All TEVA earnings
+3.3%FY2026 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q3

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.